Discovery of 12-Thiazole Abietanes as Selective Inhibitors of the Human Metabolic Serine Hydrolase hABHD16A
Files
Self archived version
final draftDate
2018Unique identifier
10.1021/acsmedchemlett.8b00442Metadata
Show full item recordMore information
Self-archived item
Citation
Ahonen, Tiina J. Savinainen, Juha R. Yli-Kauhaluoma, Jari: Kalso, Eija. Laitinen, Jarmo T. Moreira, Vânia M. (2018). Discovery of 12-Thiazole Abietanes as Selective Inhibitors of the Human Metabolic Serine Hydrolase hABHD16A. ACS Medicinal Chemistry Letters, 9 (12) , 1269–1273. 10.1021/acsmedchemlett.8b00442.Rights
© 2018 American Chemical Society. This document is the unedited Author’s version of a Submitted Work that was subsequently accepted for publication in ACS Medicinal Chemistry Letters, copyright © American Chemical Society after peer review. To access the final edit and published work see http://dx.doi.org/10.1021/acsmedchemlett.8b00442
Licensed under
Abstract
Screening of an in-house library of compounds identified 12-thiazole abietanes as a new class of reversible inhibitors of the human metabolic serine hydrolase. Further optimization of the first hit compound lead to the 2-methylthiazole derivative 18, with an IC50 value of 3.4 ± 0.2 μM and promising selectivity. ABHD16A has been highlighted as a new target for inflammation-mediated pain, although selective inhibitors of hABHD16A (human ABHD16A) have not yet been reported. Our study presents abietane-type diterpenoids as an attractive starting point for the design of selective ABHD16A inhibitors, which will contribute toward understanding the significance of hABHD16A inhibition in vivo.
Keywords
Link to the original item
http://dx.doi.org/10.1021/acsmedchemlett.8b00442Collections
- Terveystieteiden tiedekunta [1793]
